IDEEMATEC
20.5.2021 19:09:10 CEST | Business Wire | Press release
Ideematec, the leading global supplier of solar tracking systems, today announced that John Susa has joined the company in the role of Chief Sales Officer. Susa will be reporting into CEO and Co-founder Mario Eckl and will be responsible for driving global sales expansion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210520005914/en/
"We're delighted that John has joined our team," said Mario Eckl, "he has a proven track record of building solid relationships and driving strong revenue growth through identifying, developing, and realising new business opportunities. His wealth of experience in the PV industry is indispensable.”
John has spent over thirteen years working in the Solar Industry, most recently he was based in Germany, managing SMA Solar’s Global Sales and Service over the past two and a half years. During this time, SMA consolidated its customer base in Europe and North America in particular, and achieved enviable revenue growth.
Prior to that, John was responsible for establishing and growing SMA sales in both the Asia Pacific and North American regions. He is credited with successfully restructuring and leading business improvement at SMA North America. He also established SMA subsidiaries in China and Brazil, while growing business in Australia and Japan.
He moved to SMA from Trina Solar, where he spent over six years establishing a string foothold for the business in Australia and New Zealand.
“I’m thrilled to have joined the Ideematec team,” said John. “The product portfolio is remarkable, in particular the new Horizon L-Tec® solar trackers. The company also has a number of impressive flagship reference projects. I’m really looking forward to applying my experience and leveraging my industry contacts to support a shared vision of even stronger business growth and expansion.” His start date with Ideematec was Monday, May 10th.
About Ideematec
Ideematec is a trusted global supplier of solar tracking systems, headquartered in Germany. Established in 2003, the company is a tracker provider for the utility-scale sector. Ideematec pioneered the 2P high-span safeTrack Horizon™ tracker, powered by a patented decoupled drive technology. Since 2017, the company has successfully delivered some of the biggest solar facilities on three continents, including Australia (350 MW), Jordan (250 MW) and Spain (200 MW). And is actually delivering its trackers for the largest solar project in Qatar (800MW).
For more information please visit: https://www.ideematec.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005914/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom